TDS, a common factor in Type 2 diabetes patients

TDS is a common factor in patients with Type 2 diabetes and erectile dysfunction. Studies have also shown that men with Type 2 diabetes had significantly lower levels of total testosterone (–2.66 nmol/L) than those that did not have diabetes ¹².

Data from the Massachusetts Male Aging Study suggest that low levels of testosterone and sex hormone-binding globulin (SHBG) play some role in the development of insulin resistance and subsequent Type 2 diabetes ⁴⁵.

Populations of men with obesity, Type 2 diabetes and hypogonadism show a high degree of overlap. In 2001, the prevalence rate of male obesity represented an estimated 21.4 million people, 6.9 million had Type 2 diabetes and 5 million were thought to be hypogonadal ⁶.

In addition to restoring erectile function, libido and reducing fatigue, studies have demonstrated that testosterone therapy reduces insulin resistance and improves glycaemic control in hypogonadal men with Type 2 diabetes ²⁷. It has also been shown to increase lean body mass and decrease fat mass ¹⁶ and improve metabolic control ⁷.